DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteoporosis — screening already-approved drugs against its 42-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteoporosis maps to a 42-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedMedroxyprogesterone AcetateApproved drug
Structures already discussed alongside osteoporosis in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
progesterone receptor (PGR) — PGR is one of the genes in this disease's Open Targets module — part of the target space DeCure's repurposing candidates point at. The protein backbone is drawn as a cartoon. The structure has (14beta,17alpha)-17-ethynyl-17-hydroxyestr-4-en-3-one bound in it, shown as sticks.
Loading structure…
helix sheet 14beta,17alphadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1SQN · 1.451 Å · ligand (14beta,17alpha)-17-ethynyl-17-hydroxyestr-4-en-3-one (NDR). Experimental structure, not a prediction.
What the evidence adds up to
Osteoporosis is the commonest metabolic bone disease worldwide, with low trauma fracture as its clinical hallmark. Anti-resorptive therapies increase bone mineral density only to a certain extent and reduce the risk of non-vertebral fractures by 20%. Only one anabolic option is available in most parts of the world, and its effect levels off over time. Evidence for combination therapy targeting both resorption and formation is limited. Long-term adherence to treatment and identification of patients with high and imminent fracture risk after a recent fracture remain prominent challenges.
Genome-wide association studies have identified a number of loci associated with both bone mineral density and fracture risk. Early strategies for mapping osteoporosis disease genes reported only isolated associations, with replication in independent cohorts proving difficult. Neither candidate gene nor linkage studies showed association at genome-wide level of significance. The advent of massive parallel sequencing has proved successful in mapping monogenic diseases and is now being utilised in complex disease genetics.
Antiresorptive treatments are first line choices in most cases. Their major drawback is the coupling of osteoclast and osteoblast activity, meaning any reduction in bone resorption is followed by suppression of bone formation. Critical pathways and key molecules that mediate regulation of bone resorption have been identified, but their potential for translation into clinical applications is yet to be tested. The availability of drugs with different mechanisms of action has changed treatment strategies, and sequential treatment strategies are increasingly used because of the potential treatment risks associated with long-term monotherapy and the time-limited nature of osteoanabolic therapies.
What is still missing is the translation of identified genetic and molecular pathways into tested clinical applications, robust evidence for combination and sequential therapy regimens, and strategies to improve long-term adherence and the identification of patients at imminent fracture risk.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Medical Bulletin · 2015 · 56 citations · open access
The genetics of osteoporosis
AbstractINTRODUCTION: Osteoporosis is the commonest metabolic bone disease worldwide. The clinical hallmark of osteoporosis is low trauma fracture, with the most devastating being hip fracture, resulting in significant effects on both morbidity and mortality. SOURCES OF DATA: Data for this review have been gathered from the published literature and from a range of web resources. AREAS OF AGREEMENT: Genome-wide association studies in the field of osteoporosis have led to the identification of a number of loci associated with both bone mineral density and fracture risk and further increased our understanding of disease. AREAS OF CONTROVERSY: The early strategies for mapping osteoporosis disease genes reported only isolated associations, with replication in independent cohorts proving difficult. Neither candidate gene or linkage studies showed association at genome-wide level of significance. GROWING POINTS: The advent of massive parallel sequencing technologies has proved extremely successful in mapping monogenic diseases and thus leading to the utilization of this new technology in complex disease genetics. AREAS TIMELY FOR DEVELOPING RESEARCH: The identification of novel genes and pathways will potentially lead to the identification of novel therapeutic options for patients with osteoporosis.
International Journal of Gynecology & Obstetrics · 1991 · 32 citations
Prevention of osteoporosis by medroxyprogesterone acetate in postmenopausal women
AbstractThe effect of medroxyprogesterone acetate 10 mg BID alone, conjugated estrogens alone or in a combination regimen for the prevention of osteoporosis was determined in 36 postmenopausal women using single photon densitometry. No significant differences in cortical or trabecular bone mass over time were detected in women between the three treatment groups, although a slight increase in bone mass was noted in women with the combined therapy. Medroxyprogesterone acetate appears efficacious in preventing postmenopausal osteoporosis, and may be especially useful in women with contraindications to estrogen replacement therapy.
Journal of Bone Metabolism · 2018 · 26 citations · open access
Treatment of Osteoporosis: Unmet Needs and Emerging Solutions
AbstractEfficient therapies are available for the treatment of osteoporosis, however, there are still unmet needs. Anti-resorptive therapies only increase bone mineral density to a certain extent and reduce the risk of non-vertebral fractures by 20%, only one anabolic option is available in most parts of the world-the effect of which levels off over time, and the evidence for combination therapy targeting both resorption and formation is limited. In addition, identification and treatment of patients with high and imminent fracture risk following a recent fracture and long-term adherence to treatment are 2 other very prominent challenges to the management of osteoporosis. The current review will focus on emerging osteoporosis treatments and optimized use of the existing treatments that may help overcome the currently unmet needs in the management of osteoporosis.
Expert Opinion on Pharmacotherapy · 2025 · 6 citations
Current and emerging bone resorption inhibitors for the treatment of osteoporosis
AbstractINTRODUCTION: Osteoporosis is a metabolic skeletal disease characterized by low bone mass and strength, and increased risk for fragility fractures. It is a major health issue in aging populations, due to fracture-associated increased disability and mortality. Antiresorptive treatments are first line choices in most of the cases. AREAS COVERED: Bone homeostasis is complicated, and multiple factors can compromise skeletal health. Bone turnover is a continuous process regulated by the coupled activities of bone cells that preserves skeletal strength and integrity. Imbalance between bone resorption and formation leads to bone loss and increased susceptibility to fractures. Antiresorptives prevent bone loss and reduce fracture risk, by targeting osteoclastogenesis and osteoclast function and survival. Their major drawback is the coupling of osteoclast and osteoblast activity, due to which any reduction in bone resorption is followed by suppression of bone formation. EXPERT OPINION: During the last couple of decades significant progress has been made in understanding of the genetic and molecular basis of osteoporosis. Critical pathways and key molecules that mediate regulation of bone resorption have been identified. These factors may underpin novel therapeutic avenues for osteoporosis, but their potential for translation into clinical applications is yet to be tested.
[Osteoporosis therapy - Update 2025, Part 2: Sequential osteoporosis therapy].
AbstractINTRODUCTION: Osteoporosis is a chronic disease that requires lifelong therapy management that includes both non-drug and drug-based approaches. The availability of various drugs for osteoporosis therapy, characterized by different mechanisms of action, has significantly changed treatment strategies in recent years. Due to the potential treatment risks associated with long-term monotherapy and the fact that the osteoanabolic therapies used in patients with a high fracture risk are time-limited, sequential treatment strategies are increasingly being used today. The aim of this review article is to present the significance of different treatment sequences in osteoporosis drug therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
